Efficacy of cyclin-dependent kinase 4/6 inhibitors in patients with metastatic hormone positive breast cancer: a single institutional study from India
Authors:
Open Access
- 26 September 2022
- journal article
- research article
- Published by Ecancer Global Foundation in ecancermedicalscience
- Vol. 16, 1450
Abstract
Efficacy of cyclin-dependent kinase 4/6 inhibitors in patients with metastatic hormone positive breast cancer: a single institutional study from India SandKeywords
This publication has 10 references indexed in Scilit:
- Multicentric real world evidence with palbociclib in hormone positive HER2 negative metastatic breast cancer in Indian populationScientific Reports, 2021
- Efficacy and safety of palbociclib and ribociclib in patients with estrogen and/or progesterone receptor positive, HER2 receptor negative metastatic breast cancer in routine clinical practicePLOS ONE, 2021
- The Quantitative ER Immunohistochemical Analysis in Breast Cancer: Detecting the 3 + 0, 4 + 0, and 5 + 0 Allred Score CasesMedicina, 2019
- Treatment patterns and clinical outcomes among patients receiving palbociclib in combination with an aromatase inhibitor or fulvestrant for HR+/HER2-negative advanced/metastatic breast cancer in real-world settings in the US: Results from the IRIS studyThe Breast, 2019
- Phase III Randomized Study of Ribociclib and Fulvestrant in Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer: MONALEESA-3Journal of Clinical Oncology, 2018
- Metastatic Gastric cancer: Real world scenario from a developing countrySouth Asian Journal of Cancer, 2018
- Palbociclib and Letrozole in Advanced Breast CancerNew England Journal of Medicine, 2016
- Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast CancerNew England Journal of Medicine, 2016
- Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trialThe Lancet Oncology, 2016
- Revised RECIST Guideline Version 1.1: What Oncologists Want to Know and What Radiologists Need to KnowAmerican Journal of Roentgenology, 2010